PEMF therapy uses low-energy electromagnetic pulses to stimulate cell activity, primarily to speed bone healing, reduce pain, and lower inflammation. The technology has been FDA-cleared for bone repair since 1979, making it one of the longer-standing electromagnetic treatments in medicine. It works by delivering brief bursts of magnetic energy through a coil placed near the body, generating tiny electrical fields that interact with cell membranes and influence how cells produce energy.
How PEMF Works at the Cellular Level
Your cell membranes naturally carry an electrical charge. The phospholipid bilayer that forms each cell membrane acts like a tiny capacitor, separating two electrically conductive environments (the fluid inside and outside the cell) with an insulating layer in between. When a PEMF device sends an electromagnetic pulse through tissue, the electric field component of that pulse charges and discharges this natural capacitor, temporarily shifting what’s called the transmembrane potential.
That shift matters because many biological processes are voltage-dependent. Voltage-gated ion channels, which control the flow of charged particles in and out of cells, respond to changes in membrane potential. By nudging these channels open or closed, PEMF can influence everything from calcium signaling to nutrient transport.
One of the most compelling targets appears to be mitochondria, the energy-producing structures inside cells. The outer mitochondrial membrane is packed with a protein called the Voltage-Dependent Anion Channel, which controls the delivery of raw materials for energy production. Research published in Scientific Reports found that PEMF selectively stimulates the type of mitochondrial activity linked to ATP synthesis, your cells’ primary energy currency. The effect was specific: PEMF boosted energy production tied to ATP but had less impact on other forms of mitochondrial respiration. The researchers concluded that PEMF likely facilitates either the enzymatic activity of the ATP-producing machinery or the delivery of fuel to that machinery.
FDA-Cleared Uses
The FDA first approved a PEMF bone growth stimulator in November 1979, and six devices have received approval through the agency’s premarket approval pathway since then. The cleared indications include treatment of non-union fractures (bones that have stopped healing), failed bone fusions, congenital pseudarthrosis, certain fresh fractures, and as a supplement to spinal fusion surgery in both the lumbar and cervical spine.
Beyond bone healing, regulatory clearance for other uses varies by jurisdiction. European regulatory bodies have also cleared specific PEMF devices for post-operative pain and swelling. Uses for conditions like neuropathic pain or depression remain largely off-label or jurisdiction-dependent.
Bone Healing Results
PEMF’s strongest evidence base is in fracture repair, particularly for bones that have failed to heal on their own. A follow-up study tracking 1,382 patients with non-union fractures reported an overall success rate of 89.6%. An audited subset of 285 patients showed an 86.4% success rate as determined by treating physicians.
The most striking comparison comes from a double-blind, randomized, placebo-controlled trial of PEMF for tibial fractures that hadn’t healed after 16 to 32 weeks. Patients received either real PEMF treatment or a sham device for 12 weeks. At two-year follow-up, 85% of PEMF-treated fractures healed without surgery, compared to just 36% in the sham group. That’s a dramatic gap, and it’s the kind of evidence that has kept PEMF devices in orthopedic practice for decades.
Pain and Osteoarthritis
PEMF has been studied extensively for osteoarthritis, particularly in the knee. A systematic review in the Journal of Clinical Medicine analyzed 17 studies and found a significant 60% average decrease in pain scores measured on a standard visual analog scale. Global function scores, which capture pain, stiffness, and physical ability together, improved by an average of 42%. Patients using PEMF also reduced their pain medication use by 26%.
The overall treatment effect was moderate. On the visual analog scale, the pooled effect size was -0.73, which translates to a noticeable but not dramatic reduction in pain. On broader function scores, the effect was smaller at -0.34. These numbers suggest PEMF is a useful addition to osteoarthritis management rather than a standalone solution, likely most helpful as part of a broader plan that includes exercise and weight management.
Depression and Brain Stimulation
A newer application uses PEMF delivered through a helmet with seven electromagnetic coils to treat depression. This approach, called transcranial PEMF, is distinct from the better-known repetitive transcranial magnetic stimulation (rTMS) used in psychiatric clinics. The difference is enormous in terms of intensity: transcranial PEMF induces electric fields near 0.0004 volts per meter, while rTMS generates roughly 90 volts per meter.
Because PEMF stays far below the threshold needed to fire neurons directly, it works through a different mechanism. Rather than forcing neurons to activate, it appears to gently modify the brain’s natural oscillation patterns. This ultra-low intensity comes with a practical advantage: there’s no risk of treatment-induced seizures, which means patients can use the device at home rather than traveling to a clinic for each session. The side-effect profile is favorable compared to both rTMS and electroconvulsive therapy, though the evidence for effectiveness is still being built through clinical trials.
What a Typical Session Looks Like
PEMF protocols vary depending on the condition being treated and the device being used. For musculoskeletal conditions, a common clinical protocol involves 30-minute sessions at frequencies between 5 and 15 Hz, performed three times per week. Treatment courses often run 8 to 12 weeks. Some devices are large mats you lie on for full-body treatment, while others are smaller coils designed to target a specific joint or bone.
The experience is generally uneventful. You won’t feel a shock or significant sensation during treatment, though some people report a mild tingling or warmth near the coil. For bone growth stimulators, patients typically use a portable device at home for several hours daily, worn over a cast or near the fracture site. For pain and arthritis applications, sessions are shorter but spread across weeks or months.
Limitations of Current Evidence
Despite decades of use for bone healing, the evidence for many other PEMF applications remains uneven. A recent meta-analysis on PEMF for nerve pain rated the overall certainty of evidence as low under the GRADE system, which is the standard framework for evaluating medical evidence quality. This rating reflects issues that run through much of the PEMF literature: small study sizes, inconsistent treatment parameters, and mixed patient populations that make it hard to draw firm conclusions.
One persistent problem is the lack of standardization. PEMF devices vary widely in frequency, intensity, pulse shape, and treatment duration. A device pulsing at 8 Hz with a peak magnetic field of 77 millitesla is delivering a fundamentally different stimulus than one operating at 55 Hz with a fraction of that intensity. Researchers have called for future trials to standardize parameters, separate patients into more specific diagnostic categories, and use better sham devices that mimic the look and feel of real treatment without delivering the electromagnetic pulse. Until that happens, results from different studies are difficult to compare, and clinical recommendations remain tentative for most conditions outside of bone healing.